• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDOS INTERNATIONAL SARL TRUFILL N-BCA-1 GRAM KIT; TISSUE ADHESIVE FOR USE IN EMBOLIZATION OF BRAIN ARTERIOVENOUS MALFORMATIONS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDOS INTERNATIONAL SARL TRUFILL N-BCA-1 GRAM KIT; TISSUE ADHESIVE FOR USE IN EMBOLIZATION OF BRAIN ARTERIOVENOUS MALFORMATIONS Back to Search Results
Model Number 631-500
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Ischemia Stroke (4418)
Event Date 02/22/2022
Event Type  Injury  
Manufacturer Narrative
Product complaint # (b)(4).Information regarding patient weight, height, medical history, race, and ethnicity was not reported.A supplemental report will be submitted if new facts arise which materially alter information submitted in a previous mdr report.Complaint conclusion: as reported via the membrane study, a 78-year-old male (subject (b)(6)) with a history of cardiac arrhythmia, coronary artery disease (cad), diabetes, head injury within the past 12 months, and controlled hypertension underwent middle meningeal artery (mma) embolization of a left frontal chronic subdural hematoma (csdh) on (b)(6) 2022 and experienced a right posterior cerebral artery infarct on (b)(6) 2022.Computed tomography (ct) scan of the brain without contrast was performed as diagnostic test/evaluation.The event has not resolved.Per the principal investigator (pi), the event was moderate in severity and possibly related to the study device and study procedure (i.E., mma embolization).The event was considered serious by the pi as the event required prolonged hospitalization.The patient was discharged to a rehabilitation center on (b)(6) 2022 with modified rankin scale (mrs) score of 4.The patient was randomized into the non-surgical medical management (nsmm) and mma embolization cohort of the study.His baseline markwalder grading scale (mgs) score was 1 and modified rankin scale (mrs) score was 2.The csdh thickness was 17mm and volume 58.4ml.The mma embolization study procedure was performed on (b)(6) 2022 via right radial access.Trufill n-bca 1x1 gram glue (631500/jr4806) (4:1 oil: n-bca ratio) was delivered via a headway duo microcatheter (microvention).No vasospasm nor non-target embolization occurred during the procedure.In the opinion of the treating physician, the mma embolization was successful.The device remains implanted, therefore, no further investigation can be performed.A manufacturing record evaluation (mre) was performed for the finished device jr4806 number, and no non-conformances related to the malfunction were identified.Cerebral infarction is a known potential complications associated with this type of embolization procedures and is listed in the trufill n-bca instructions for use (ifu) as such.With the amount of information available, it is not possible to draw a conclusion between the device and the reported event.However, there are patient, procedural, and pharmacological factors that may have contributed to the cerebral infarction rather than the design or manufacture of the device.There is no evidence to suggest a device malfunction or quality issue.Cerebral infarction is a condition which may require medical and/or invasive intervention and hospitalization to prevent permanent impairment.Furthermore, the pi assessed the event as possibly related to the study device.Thus, the event is considered serious , the file will be re-reviewed if additional information is received at a later date.As part of the cerenovus quality process, all devices are manufactured, inspected, and released to approved specifications.As part of the post market surveillance program, information from this complaint is trended to identify statistical signals for consideration of further correction action.Since there was no evidence to suggest the event was related to a manufacturing or design issue, no corrective actions will be taken at this time.
 
Event Description
As reported via the membrane study, a 78-year-old male (subject (b)(6)) with a history of cardiac arrhythmia, coronary artery disease (cad), diabetes, head injury within the past 12 months, and controlled hypertension underwent middle meningeal artery (mma) embolization of a left frontal chronic subdural hematoma (csdh) on (b)(6) 2022 and experienced a right posterior cerebral artery infarct on (b)(6) 2022.Computed tomography (ct) scan of the brain without contrast was performed as diagnostic test/evaluation.The event has not resolved.Per the principal investigator (pi), the event was moderate in severity and possibly related to the study device and study procedure (i.E., mma embolization).The event was considered serious by the pi as the event required prolonged hospitalization.The patient was discharged to a rehabilitation center on (b)(6) 2022 with modified rankin scale (mrs) score of 4.The patient was randomized into the non-surgical medical management (nsmm) and mma embolization cohort of the study.His baseline markwalder grading scale (mgs) score was 1 and modified rankin scale (mrs) score was 2.The csdh thickness was 17mm and volume 58.4ml.The mma embolization study procedure was performed on (b)(6) 2022 via right radial access.Trufill n-bca 1x1 gram glue (631500/jr4806) (4:1 oil: n-bca ratio) was delivered via a headway duo microcatheter (microvention).No vasospasm nor non-target embolization occurred during the procedure.In the opinion of the treating physician, the mma embolization was successful.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TRUFILL N-BCA-1 GRAM KIT
Type of Device
TISSUE ADHESIVE FOR USE IN EMBOLIZATION OF BRAIN ARTERIOVENOUS MALFORMATIONS
Manufacturer (Section D)
MEDOS INTERNATIONAL SARL
chemin-blanc 38
le locle neuchatel CH-24 00
SZ  CH-2400
Manufacturer (Section G)
CODMAN AND SHURTLEFF, INC
325 paramount dr
raynham MA 02767
Manufacturer Contact
michelleann garcia
31 technology dr
irvine, CA 92618
6465917981
MDR Report Key14143238
MDR Text Key293461415
Report Number3008114965-2022-00300
Device Sequence Number1
Product Code KGG
UDI-Device Identifier10886704029151
UDI-Public10886704029151
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P990040
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 04/19/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/19/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date08/31/2023
Device Model Number631-500
Device Catalogue Number631500
Device Lot NumberJR4806
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received04/01/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured12/28/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
HEADWAY DUO MICROCATHETER (MICROVENTION)
Patient Outcome(s) Hospitalization;
Patient Age78 YR
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-